Fig. 1From: Clinical spectrum, over 12-year follow-up and experience of SGLT2 inhibitors treatment on patients with glycogen storage disease type Ib: a single-center retrospective studyNeutrophil count (A), hematocrit (B), hemoglobin (C), and platelet count (D) of 14 glycogen storage disease type Ib patients before and after empagliflozin treatmentBack to article page